Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.35 |
| ▸ | JAK1 | P23458 | 10/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385548 | 0.99 | JAK2 (0.34) | JAK2JAK1ALOX5APFEN1LMNA | |
| SCHEMBL25170319 | 0.94 | JAK2 (0.37) | JAK2JAK1ALOX5APFEN1LMNA | |
| SCHEMBL25170404 | 0.94 | JAK2 (0.33) | JAK2JAK1TBK1 | |
| SCHEMBL30403731 | 0.94 | JAK2 (0.35) | JAK2JAK1LMNATP53THRB | |
| SCHEMBL25176181 | 0.92 | TBK1 (0.33) | JAK2JAK1ALOX5APFEN1LMNA | |
| SCHEMBL30385462 | 0.92 | CYP2C9 (0.34) | JAK2JAK1ALOX5APFEN1LMNA | |
| SCHEMBL30384803 | 0.91 | JAK2 (0.34) | JAK2JAK1LMNATP53TYK2 | |
| SCHEMBL28982168 | 0.90 | JAK2 (0.33) | JAK2JAK1ALOX5APFEN1TYK2 | |
| SCHEMBL28982170 | 0.90 | JAK2 (0.33) | JAK2JAK1ALOX5APFEN1TYK2 | |
| SCHEMBL28982205 | 0.89 | PTK6 (0.36) | JAK2JAK1ALOX5APFEN1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | JAK2 57/4885JAK1 127/4885ALOX5AP 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.